Axoltis says its Phase 2 study for an experimental ALS drug failed

The French biotech Axoltis Pharma reported a Phase 2 failure in ALS on Tuesday morning, but suggested it found a small signal to move the drug forward amid a noisy dataset. Researchers were testing whether ...